Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study

Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study

•In this phase II trial of atezolizumab and bevacizumab in advanced MCC patients, the ORR was 64 %, with 27 % complete responses.•Atezolizumab and bevacizumab was well tolerated, grade 3 TRAEs were hypertension (18 %), proteinuria (9 %), and hepatitis (9 %).•Patients with CR had a predicted inflamed...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oral oncology 2024-04, Vol.151, p.106747-106747, Article 106747
Hauptverfasser: de Sousa, L. Guimaraes, Liu, S., Bhosale, P., Altan, M., Darbonne, W., Schulze, K., Dervin, S., Yun, C., Mahvash, A., Verma, A., Futreal, A., Gite, S., Cuentas, E. Parra, Cho, W.C., Wistuba, I., Yao, J.C., Woodman, S.E., Halperin, D.M., Ferrarotto, R.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•In this phase II trial of atezolizumab and bevacizumab in advanced MCC patients, the ORR was 64 %, with 27 % complete responses.•Atezolizumab and bevacizumab was well tolerated, grade 3 TRAEs were hypertension (18 %), proteinuria (9 %), and hepatitis (9 %).•Patients with CR had a predicted inflamed tumor microenvironment based on the RNA signature.•Atezolizumab plus bevacizumab demonstrated encouraging activity in patients with advanced MCC.
ISSN:1368-8375
1879-0593
DOI:10.1016/j.oraloncology.2024.106747